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ABSTRACT
This study investigated the clinical significance of keratin 5 and 6 expression 
in serous ovarian cancer progression and chemotherapy resistance. KRT5 and KRT6 
(KRT6A, KRT6B & KRT6C) gene expression was assessed in publically available 
serous ovarian cancer data sets, ovarian cancer cell lines and primary serous ovarian 
cancer cells. Monoclonal antibodies which detect both K5/6 or only K5 were used 
to assess protein expression in ovarian cancer cell lines and a cohort of high grade 
serous ovarian carcinomas at surgery (n = 117) and after neoadjuvant chemotherapy 
(n = 21). Survival analyses showed that high KRT5 mRNA in stage III/IV serous 
ovarian cancers was significantly associated with reduced progression-free (HR 1.38, 
P < 0.0001) and overall survival (HR 1.28, P = 0.013) whilst high KRT6 mRNA was 
only associated with reduced progression-free survival (HR 1.2, P = 0.031). Both high 
K5/6 (≥ 10%, HR 1.78 95% CI; 1.03−2.65, P = 0.017) and high K5 (≥ 10%, HR 1.90, 
95% CI; 1.12−3.19, P = 0.017) were associated with an increased risk of disease 
recurrence. KRT5 but not KRT6C mRNA expression was increased in chemotherapy 
resistant primary serous ovarian cancer cells compared to chemotherapy sensitive 
cells. The proportion of serous ovarian carcinomas with high K5/6 or high K5 
immunostaining was significantly increased following neoadjuvant chemotherapy. 
K5 can be used to predict serous ovarian cancer prognosis and identify cancer cells 
that are resistant to chemotherapy. Developing strategies to target K5 may therefore 
improve serous ovarian cancer survival.
INTRODUCTION
Ovarian cancer is the most lethal gynaecological 
cancer and the sixth most common cause of cancer related 
death among Western women [1]. Although ovarian 
cancers represent only 30% of cancers of the female 
genital tract, they are responsible for half of the deaths [1]. 
The disproportionately high mortality rate is attributed to 
the late presentation of the disease. Despite advances in 
surgery and chemotherapies, no substantial improvement 
in ovarian cancer survival has been observed over the 
last two decades [2]. A greater understanding of the 
mechanisms involved in the progression of ovarian cancer 
will aid in the discovery of novel molecular prognostic 
indicators as well as new therapeutic targets. To increase 
our understanding of the molecular mechanisms involved 
in ovarian cancer progression and to identify novel 
therapeutic targets we recently studied the interaction of 
ovarian cancer and peritoneal cells [3–5]. Keratins K5 
and K6c were amongst the proteins that were identified in 
the ovarian cancer peritoneal cell co-culture secretome by 
MALDI-TOF/TOF mass spectrometry [5].
Oncotarget2www.impactjournals.com/oncotarget
Keratins are intermediate filament proteins 
responsible for structural integrity of epithelial cells and 
play an important role in epithelial cell protection. They 
also play roles in cell polarization, cell size regulation, 
protein translation and organelle positioning [6]. Fifty four 
functional keratin proteins have been identified in human 
epithelial cells including 28 type I (acidic forms, K9-K28) 
and 26 type II (basic forms, K1-K8 and K71-K74) proteins 
[7, 8]. They contain a central rod of ~310 amino acids with 
a helical conformation flanked by non-helical head and 
tail domains of variable length [9]. A characteristic feature 
of keratin proteins is their pairing with other keratin 
proteins. They form obligate heterodimers between a type 
I keratin and a type II keratin via their rod domains and 
the resulting heterodimers and tetramers form the basic 
building units of the keratin filaments [7, 8].
K5 (encoded by gene KRT5) is a high molecular 
weight (predicted 62.6 kDa), basic type keratin expressed 
in the basal, intermediate, and superficial layers of 
stratified epithelia as well as transitional epithelia and 
complex epithelium [9]. It is most often complexed with 
K14 [9]. K5 positive cells have been identified in both 
luminal and basal epithelium of the normal breast and 
K5 has been implicated as a stem cell marker [10, 11]. 
A recent study has highlighted that K5 expressing basal 
cells in the healthy and regenerating urothelium are 
self-renewing and unipotent [12].
K6 protein is also a high molecular weight 
(predicted 60.3 kDa), basic type keratin known to be 
expressed by proliferating squamous epithelia and 
usually complexes with K16 [9]. Three isoforms of K6 
exist (K6a, K6b, and K6c) which are encoded by three 
distinct genes: KRT6A, KRT6B, and KRT6C [13, 14]. K6a 
is the most abundant, representing about 77% of all forms 
found in epithelia and shares at least 97.6% amino acid 
identity with other K6 proteins. K6a has been detected in 
subpopulations of luminal and ductal myoepithelial cells 
in human mammary glands [15]. A high proliferative 
population of K6a positive cells has also been described 
in the prostate gland [16]. There have been only a few 
studies which have investigated the expression of the K6c 
isoform in human tissues as until recently there was a lack 
of isoform-specific gene probes and antibodies.
Monoclonal antibodies to K5 and K5/6 have 
been used to identify basal-like triple negative breast 
cancers [17, 18] and high K5/6 expression was found 
to be associated with an increased risk of breast cancer 
relapse and death [17, 19, 20]. Focal K5/6 expression 
has also been described in adenocarcinomas of the 
endometrium, pancreas and ovary [21, 22]. In addition, 
K5+ subpopulation of cells have been identified in ER+ 
PR+ luminal breast cancers [23, 24] and are increased in 
patients whose luminal breast cancers develop resistance 
to endocrine treatment and chemotherapy [25, 26].
Whilst other keratins have been shown to have 
diagnostic or prognostic utility in ovarian cancer [27–30], 
limited studies to date have examined K5 and K6 
expression in this malignancy. We therefore investigated 
the prognostic significance of KRT5 and KRT6 mRNA 
expression in publically available serous ovarian cancer 
data sets [31]. Additionally, monoclonal antibodies which 
detect both K5/6 or only K5 were used to assess protein 
expression in ovarian cancer cell lines and cohorts of 
high grade serous ovarian carcinomas at surgery and 
after neoadjuvant chemotherapy. Furthermore, KRT5 and 
KRT6C mRNA expression was assessed in chemotherapy 
sensitive and chemotherapy resistant primary serous 
ovarian cancer cells derived from patient ascites. We 
also evaluated whether K5+ cells are increased in serous 
ovarian cancer patients following chemotherapy treatment. 
To our knowledge, this is the first study to investigate the 
relationships between KRT5 mRNA, KRT6 mRNA, K5/6, 
and K5 protein expression with serous ovarian cancer 
patient outcome. 
RESULTS 
KRT5, KRT6C mRNA and K5/6 protein 
expression in ovarian cancer cell lines 
Using qRT-PCR KRT5 is expressed by metastatic 
OVCAR-5, OV-90, and SKOV-3 ovarian cancer cells, 
as well as by poorly metastatic OVCAR-3 cells but not 
the peritoneal cell line, LP-9 (Figure 1A). KRT6C was 
expressed by all ovarian cancer cell lines as well as LP-9 
cells (Figure 1B). The K5/6 antibody detected bands at 
~52 kDa in all cell line extracts and faint bands at ~56 kDa 
in protein extracts from OVCAR-5, OV-90 and SKOV-3 
cells (Figure 1C). Using human ovarian cancer tissue 
extracts shown to express high and low K5/6 and K5 
positivity (see inserts in Figure 1C and 1D) and antibodies 
to only K5, we confirmed that the 56 kDa and 52 kDa 
bands were K5 and K6, respectively. Two bands at ~52 
kDa and ~56 kDa were observed with the K5/6 antibody 
in the ovarian cancer tissue extracts (Figure 1C), however 
the K5 antibody (Abcam) only detected a single band at 
~56 kDa in the ovarian cancer tissue (Figure 1D). 
K5/6 and K5 are elevated in serous carcinoma 
tissues
K5/6 immunostaining was abundant in the skin 
epidermis (Figure 2A) but little or no staining was observed 
in the ovarian surface epithelium (OSE) of normal ovaries 
(8/8, Figure 2B, Table 1A). High K5/6 immunostaining 
(score 2 or 3) was present in 25% (2/8) of the benign 
serous cystadenoma (Figure 2C, Table 1A), 60% (6/10) 
high grade serous borderline tumors (Figure 2D, Table 1A) 
and 29.9% (35/117) of the serous ovarian cancer cases 
(Table 1A). Sixteen percent (19/117) of the serous ovarian 
cancer tissues were negative for K5/6. Examples of low 
(score = 1) and high (score = 3) K5/6 immunostaining 
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in serous ovarian cancer tissues are shown in Figure 2E 
and 2F, respectively. K5/6 immunostaining was increased 
in serous borderline tumors and serous carcinomas 
compared to normal ovaries (P = 0.006, Chi-Square 
test, Table 1A). Similar staining patterns were observed 
with a monoclonal antibody which detects only K5 
(Table 1C), (Supplementary Figure 1). However, a higher 
proportion of serous carcinomas (66%, 70/106) had high 
K5 immunostaining compared to K5/6 immunostaining. 
Neither K5/6 nor K5 immunostaining were associated with 
patient age, FIGO stage, tumor grade or the presence of 
residual disease (Supplementary Table 1).
Relationship of KRT5 and KRT6 mRNA and 
K5/6 protein expression with patient outcome
Using the publically available Kaplan-Meir online 
plotter tool which incorporates gene expression data 
from 13 ovarian cancer sets including the TCGA dataset 
[31], high KRT5 expression was associated with reduced 
progression-free survival (PFS, HR 1.38; 95% CI 1.16–1.64, 
P < 0.0001, Figure 3A) and overall survival (OS, HR 1.28 
95%; CI 1.05–1.56, P = 0.013, Figure 3B). High KRT6 
expression was also associated with reduced PFS (HR 
1.26; 95% CI 1.07–1.47, P = 0.005, Figure 3C) but not OS 
(Figure 3D). No statistical correlation was found between 
KRT5 or KRT6 expression with patient age at diagnosis, 
tumor stage, tumor grade, or size of residual tumor after 
cytoreductive surgery in the TCGA dataset (data not shown). 
We confirmed in a cohort of advanced stage serous 
ovarian cancers that patients with high K5/6 or high K5 
immunostaining (≥ 10.0%) had a significantly reduced 
PFS compared to patients with low K5/6 or low K5 
positivity (< 10.0%, Figure 4A, 4C). The 24 months 
PFS rate was 34.4% in the group of patients with K5/6 
positivity < 10% and only 10.5% in the group of patients 
with K5/6 positivity ≥ 10%. The 24 months PFS rate 
was 48.5% in the group of patients with K5 positivity 
< 10% and only 27.7% in the group of patients with K5 
positivity ≥ 10%. Neither K5/6 nor K5 immunostaining 
Figure 1: KRT5, KRT6C mRNA, K5/6 and K5 expression in ovarian cancer cell lines. (A) KRT5 mRNA expression in 
ovarian cancer cell lines and LP-9 cells. (B) KRT6C mRNA expression in ovarian cancer cell lines and LP-9 cells. Relative expression was 
normalized to the house keeping gene β-actin using the 2-∆∆CT method with the same calibrator (OVCAR-3). Data is expressed as the mean 
fold change ± SEM from 4-11 individual RNA samples obtained from 2-4 independent experiments. (C) Equal amounts protein for the cell 
lines (40 µg) and ovarian cancer tissue extracts (5 µg) were run on a 4-20% SDS-PAGE gel and immunoblotted with mouse monoclonal K5/6 
antibody (1/200, clone D5/16 B4, Dako). K5/6 antibody detected K6 bands at ~52 kDa in all cell line extracts and faint K5 bands at ~56 kDa 
in cell extracts from OVCAR-5, OV-90 and SKOV-3 cells. Both K5 and K6 were detected in ovarian cancer tissue extracts. White asterisks 
indicate faint K5 bands detected with K5/6 antibody. (D) Western blotting with rabbit monoclonal K5 antibody (1/5000, clone EPR1600Y, 
Abcam) antibody using the same protein samples from (C) confirmed K5 expression in ovarian cancer tissue extracts. A mouse monoclonal 
antibody to β-actin (1/10,000, clone AC-15, Sigma Aldrich A3854) was used as a loading control. Ovarian cancer tissues sections with high 
and low K5/6 (C) or K5 (D) immunostaining were used as positive controls for the western blots (scale bar = 50 µm).
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was associated with OS (Figure 4B, 4D). Cox regression 
analysis also indicated that patients with high K5/6 
positivity (≥ 10%) had a 1.78 fold increased risk of disease 
relapse (95% CI; 1.01–2.66, P = 0.017, Table 2). High K5 
positivity was associated with a 1.90 fold increased risk of 
disease relapse (95% CI; 1.12–3.19, P = 0.017, Table 2). 
Other clinical and pathological parameters including 
patient age, clinical stage, tumor grade, and the presence 
of residual disease were not associated with PFS or OS in 
this advanced stage serous ovarian cancer cohort (Table 2).
KRT5 mRNA and K5 protein levels are elevated 
following chemotherapy treatment
K5/6 was increased in serous ovarian cancer tissues 
following chemotherapy compared with chemonaïve 
tissues (P < 0.0001, Table 1B). Increased K5/6 
immunostaining is evident in the images in Figure 2G 
and 2H that are an example of matching tissues from the 
same patient before and after chemotherapy treatment, 
respectively. Similar results were observed with the K5 
monoclonal antibody (Table 1C, Supplementary Figure 
1G and 1H). These findings are supported by mRNA 
expression studies in chemosensitive and chemoresistant 
primary ovarian cancer cells. KRT5 but not KRT6C 
mRNA expression was increased in primary cells derived 
from patients’ ascites with recurrent chemoresistant 
disease (n = 10) compared with primary cells from 
patients who responded to the chemotherapy treatment 
(n = 9; Figure 5A and 5B, P = 0.0006, Mann Whitney 
U test). KRT5 (Figure 5A), KRT6C mRNA (Figure 5B) 
and K5 protein (Figure 5C and 5D) were increased in 
OVCAR-5 cells made resistant to carboplatin (OVCAR-
5-CBPR) compared with the parental OVCAR-5 cells by 
immunofluoresence. Furthermore, treatment with an IC50 
dose of carboplatin significantly increased the number of 
K5+ cells in 4 serous ovarian cancer cell lines (OVCAR-5, 
OVCAR-3, OAW28 and COV362) (Figure 5C and 5D).
DISCUSSION
High grade serous ovarian carcinomas account 
for nearly 70% of ovarian malignancies. They are 
characterized by high initial chemosensitivity to platinum 
based therapies, however 75% of patients relapse after 
treatment and subsequently become chemotherapy 
resistant [32]. The development of more effective 
molecularly targeted therapies to improve survival is 
urgently required. In this study we show that 1) KRT5 
and KRT6C are expressed by ovarian cancer cell lines, 2) 
KRT5 expression levels predict reduced PFS and OS for 
serous ovarian cancer patients, 3) KRT6 expression levels 
predict reduced PFS but not OS for serous ovarian cancer 
patients, 4) Both high K5/6 or high K5 positivity in serous 
ovarian cancers can predict reduced PFS but not OS, 
5) K5/6 and K5 immunostaining is increased in serous 
ovarian cancers following neoadjuvant chemotherapy, 6) 
KRT5 expression levels but not KRT6C are increased in 
serous primary cells derived from patients’ ascites with 
chemoresistant disease and 7) K5 protein expression is 
increased in serous ovarian cancer cell lines following 
carboplatin treatment. Our findings indicate that K5 
expression could be used to predict serous ovarian cancer 
prognosis and may be used to identify cancer cells that are 
resistant to chemotherapy.
K5 is usually detected using a K5/6 combination 
monoclonal antibody (clones D5/16B4) as it is closely 
related to K6. Co-expression of K5 and K6 has been 
reported in a number of different types of neoplasms 
including basal cell carcinoma [33], prostate cancer 
[34, 35], ductal breast carcinoma [36–38], mesothelioma 
[39, 40], lung carcinomas [41], melanoma, basal cell 
Figure 2: K5/6 expression in human ovarian tissues. K5/6 immunohistochemistry using mouse monoclonal K5/6 antibody (1/50, 
clone D5/16 B4, DAKO) using Tris buffer (pH 9.0) microwave antigen retrieval. Human skin (A), normal ovary (B), benign serous 
cystadenoma (C), serous borderline tumor (D), serous carcinoma with low K5/6 immunostaining (E) serous carcinoma with high K5/6 
immunostaining (F). K5/6 immunostaining in tissues obtained from the same patient at diagnosis (G) and following treatment carboplatin 
and paclitaxel (H). Scale bar = 100 µm. All images are same magnification.
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carcinoma, and salivary gland tumors [22]. K5/6 
overexpression is associated with poor prognosis of basal-
like breast cancers [17, 18, 42] and was found to be an 
independent indicator of recurrence-free survival and/or 
OS in breast cancer [17, 19, 20, 43]. The K5/6 monoclonal 
antibody has been used for the diagnosis of poorly 
differentiated squamous carcinomas and undifferentiated 
nasopharyngeal carcinomas [21, 22]. It can distinguish 
between small cell lung carcinomas which are K5 negative 
and malignant mesothelioma which are K5 positive 
[21, 22]. K5/6 has superior sensitivity and reliability in 
differentiating between benign and malignant prostate 
glands when compared with K903 (high molecular weight 
keratins); and [34] it has been used successfully in a five 
antibody panel (which also targets TRIM29, CEACAM5, 
SLC7A5, MUC1) to better classify the subtypes of 
lung carcinoma [44]. The expression of K5/6 together 
with p63 has also been used to differentiate between 
adenosquamous carcinomas and adenocarcinomas in 
pleural effusion samples [45, 46]. Recently, K5 positive 
basal cells have also been identified as progenitors of 
bladder cancers [47].
Several studies have investigated the expression of 
K5/6 in ovarian cancer but to date K5 or K6 expression 
has not been linked with ovarian cancer outcome. The 
incidence of K5/6 positivity (29.9%, Table 1B) in our study 
was similar to that observed in previous ovarian cancer 
studies which ranged from 25% to 55.4% [22, 48, 49]. 
However we observed a higher proportion of serous 
carcinomas (66%, Table 1C) with high K5 immunostaining 
which is comparable to a recent study reporting 50% K5 
positivity in serous ovarian carcinomas [50]. Our finding 
is in agreement with the study by Bhargava et al, 2008 
who found that a monoclonal antibody to only K5 (clone 
Table 1: Comparison of K5/6 and K5 immunostaining in different tissues groups
A. K5/6 immunostaining in normal ovaries, benign serous cystadenomas, serous borderline tumors and serous 
ovarian carcinomas
Tissue
K5/6 immunostaining (positivity groups)





































Chi-squared test P = 0.006
B. K5/6 immunostaining in chemonaive serous ovarian cancers and post chemotherapy treatment
Tissue n
K5/6 immunostaining (positivity groups)
< 10% ≥ 10%
Serous ovarian carcinomas (chemonaïve) 117 82/117(70.1%)
35/117
(29.9%)
Serous ovarian carcinoma (Post chemotherapy 21 3/21(14.3%)
18/21
(85.7%)
Fisher exact test P < 0.0001
C. K5 immunostaining in chemonaive serous ovarian cancers and post chemotherapy treatment
Tissue n
K5 immunostaining (positivity groups)
< 10% ≥ 10%
Serous ovarian carcinomas (chemonaïve) 106 36/106(34.0%)
70/106
(66.0%)
Serous ovarian carcinoma (Post chemotherapy 21 1/21(4.8%)
20/21
(95.2%)
Fisher exact test P = 0.007
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XM26) was more sensitive than the K5/6 monoclonal 
antibodies (clones D5/16B4) in identifying basal-like 
breast carcinomas and reported a sensitivity of 97% for 
K5 but only 59% for K5/6 [18]. The K5 antibody (clone 
EPR1600Y) used in our study is raised to a synthetic 
peptide in the head domain of keratin 5 whilst the K5/6 
antibody clones were raised against purified keratin 
proteins. It has been suggested that the lower sensitivity 
of the K5/6 antibodies by immunohistochemistry may be 
caused by an interference between each other’s antigenic 
binding sites by steric hindrance [18]. 
Gene expression studies have previously identified 
only KRT5 mRNA and not KRT6 isoforms in normal 
breast and basal-like breast cancer in humans [11, 21, 51]. 
Consequently in normal breast tissues and cancer, the 
K5/6 antibody is thought to target only K5 [52]. We found 
Figure 3: Kaplan Meier survival analysis showing association of KRT5 and KRT6 mRNA expression with patient 
outcome. (A) Progression-free survival curve in stage III/IV serous ovarian cancers patients with low or high levels of KRT5 (Affymetrix 
probe set 201820_at). (B) Overall survival curve in stage III/IV serous ovarian cancers patients with low or high levels of KRT5 (Affymetrix 
probeset 201820_at). (C) Progression-free survival curve in stage III/IV serous ovarian cancers patients with low or high levels of KRT6 
(Affymetrix probeset 209126_x_at, which detects all KRT6 isoforms). (D) Overall survival curve in stage III/IV serous ovarian cancers 
patients with low or high levels of KRT6 (Affymetrix probeset 209126_x_at, which detects all KRT6 isoforms).
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LP-9 peritoneal cells to express KRT6C but not KRT5. We 
confirmed that K6 protein is expressed in ovarian cancer 
cell lines and LP-9 cells but only faint K5 bands could be 
detected with K5/6 in OVCAR-5, OV-90 and SKOV-3 cell 
extracts. The low expression of K5 protein in ovarian cancer 
cell lines was confirmed by immunofluorescence as only 
10–15% of ovarian cancer cells had detectable K5 protein 
without carboplatin treatment (see Figure 5C and 5D). 
The observed molecular weights of K5 (56 kDa) and K6 
(52 kDa) were close to the predicted molecular weight of 
K5 (62 kDa) and K6 (60 kDa), respectively, and consistent 
with previous studies that have observed K5 at 56 kDa in rat 
liver cancer [53] and K6 at 50 kDa in bladder cancer [54].
K5/K14 form the main keratins in keratinocytes of 
stratified squamous epithelia of the epidermis as well as 
mucosal non-keratinizing stratified squamous epithelia [9]. 
K5 is strongly expressed in the undifferentiated basal 
cell layer which contains stem cells and is reduced 
in the differentiating suprabasal cell layers [7]. Our 
immunostaining in human skin using the K5/6 and 
K5 antibodies concur with this finding. Recent studies 
have reported that K5/K14 modulates cell proliferation 
and cell differentiation in the stratified epithelia via the 
P13K/Akt pathway and K5/K14 negatively regulates cell 
differentiation via the Notch 1 signaling pathway [55]. 
Consequently K5/K14 is thought to play an important role 
in the maintenance of cell proliferation in the basal layer 
of stratified epithelia. It is likely that K5 regulates similar 
pathways in serous ovarian cancer cells. 
Greater than 50% of ER+PR+ tumors contain ER-
PR-K5+ subpopulations [26] and K5+ cells are increased in 
ER+ breast tumors following treatment with neoadjuvant 
endocrine therapy [25]. ER-PR-K5+ luminal breast cancer 
cell populations, termed ‘luminobasal’ cells exhibiting 
enhanced progenitor properties can be induced by 
progestins, glucocorticoids, as well as mineralocorticoids 
Figure 4: Kaplan Meier survival analysis showing association of expression of K5/6 and K5 alone with patient outcome. 
(A) Progression-free survival curve in stage III/IV serous ovarian cancers patients with high K5/6 immunostaining (≥ 10%, n = 30) and 
low K5/6 immunostaining (< 10%, n = 73, P = 0.014, log rank test). (B) Overall survival curve in stage III/IV serous ovarian cancers 
patients with high K5/6 immunostaining (> 10%, n = 33) and low K5/6 immunostaining (< 10%, n = 80, P = 0.673, log rank test). (C) 
Progression-free survival curve in stage III/IV serous ovarian cancers patients with high K5 immunostaining (≥ 10%, n = 63) and low K5 
immunostaining (< 10%, n = 31, P = 0.015, log rank test). (D) Overall survival curve in stage III/IV serous ovarian cancers patients with 
high K5 immunostaining (≥ 10%, n = 69) and low K5 immunostaining (< 10%, n = 18, P = 0.144, log rank test).
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[26, 56–58] and blocked by anti-progestins and prolactin 
[57]. Interestingly, these K5+ breast cancer cells were found 
to be less sensitive to 5-fluorouracil and docetaxel in in vitro 
culture and exhibited reduced apoptosis [25]. A recent study 
investigated metastasis formation in ovariectomized mice 
injected with luminal breast cancer cell lines and assessed 
the metastatic process following treatment with estradiol or 
estradiol + progestin [59]. The untreated ovariectomized 
mice were metastasis-free until they were supplemented 
with estradiol or estradiol + progestin. Unlike the parental 
cells that were predominately ER+PR+K5- the metastases 
formed following estradiol or estradiol + progestin contained 
significantly increased proportions of ER-PR-K5+ cells 
(6–30%). This finding may have important implications for 
women on hormonal contraception or replacement therapy 
who may harbor dormant K5+ micrometastases. It has also 
been suggested that basal-like breast cancers in BRCA1 
deficient women may potentially arise from K5+ luminal 
progenitors [23]. Compounds that can effectively target 
these K5+ cells have the potential to improve the outcome 
of luminal breast cancers and basal-like breast cancers. 
Targeting K5+ cells may also be effective in reducing 
recurrence in patients with serous ovarian carcinoma. 
Indeed many similarities have been observed between 
basal-like breast cancers and serous ovarian carcinoma [60].
A recent study by Corr et al (2015) demonstrating 
that K5+ ovarian cancer cells were more resistant to 
cisplatin-induced apoptosis than K5- cells has suggested 
that K5 is a marker of a chemoresistant subpopulation 
of ovarian cancer cells [50]. Their observation that 
the number of K5+ cells increased following cisplatin 
treatment agrees with the carboplatin data presented 
in our study. We additionally showed that K5 and K5/6 
immunostaining is significantly increased following 
neoadjuvant chemotherapy treatment and that KRT5 
mRNA is increased in chemoresistant compared to 
chemosensitive serous primary ovarian cancer. These 
findings support the notion that K5 plays an important role 
in the development chemotherapy resistance. 
In conclusion, this study found for the first time 
that serous ovarian carcinomas with increased KRT5 
and KRT6 mRNA expression, as well as increased K5 or 
K5/6 immunostaining have an increased risk of disease 
relapse. K5/6 and K5 expression may therefore be used for 
predicting the prognosis of serous ovarian cancer patients 
and to aid patient management. In addition our findings 
that K5 is increased following carboplatin treatment and 
in chemotherapy resistance cells suggest that K5 could 
also be used to identify cancer cells that are resistant to 
chemotherapy. Developing strategies to target K5 may 




The human ovarian cancer cell lines OVCAR-3, 
SKOV-3, and OV-90 were purchased from American 
Type Culture Collection (ATCC, VA, USA). OVCAR-5 
Table 2: Univariate cox regression analyses for progression-free survival and overall survival
Progression-free survival Overall survival
Variable Relative risk 95% CI P value Variable Relative risk 95% CI P value
Agea
(n = 112) 1.23 0.80–1.90 0.340 Age (n = 120) 1.25 0.79−1.97 0.342
Tumor stageb
(n = 112) 0.24 0.19–1.50 0.540
Tumor stage
(n = 120) 0.52 0.26−1.99 0.718
Tumor gradec
(n = 112) 0.89 0.57–1.62 0.962 Tumor grade (n = 122) 0.96 0.57−1.70 0.985
Residual 
diseased
(n = 89) 
1.47 0.75–2.88 0.260 Residual disease(n = 96) 2.20 0.99−4.90 0.053
K5/6e
(n = 102) 1.78 1.01–2.66 0.017 K5/6 (n = 106) 1.02 0.60−1.74 0.929
K5f
(n = 91) 1.90 1.12–3.19 0.017
K5
(n = 99) 1.40 0.82−2.44 0.234
NOTE: P values highlighted in bold indicate P < 0.05.
a = Age a dichotomous variable, cut point < 55 vs ≥ 55.
b = Tumor stage (FIGO stage III vs FIGO stage IV).
c = Tumor grade (moderate vs poor).
d = Residual disease status (negative vs positive).
e = K5/6 (% positive cells) as a dichotomous variable, cut point < 10 vs ≥ 10.
f = K5 (% positive cells) as a dichotomous variable, cut point < 10 vs ≥ 10.
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Figure 5: KRT5, KRT6C mRNA and K5 protein expression in serous ovarian cancer cell lines following chemotherapy 
treatment. KRT5 (A) and KRT6C (B) expression in chemotherapy resistant primary serous ovarian cancer cells (n = 10) compared to 
chemotherapy sensitive cells (n = 9) and OVCAR5 CBPR made resistant to carboplatin (CBP). KRT5 but not KRT6C was significantly 
increased in chemotherapy resistant cells (n = 10) compared to chemotherapy sensitive cells (n = 9, *P = 0.0006, Mann Whitney U test). 
Both KRT5 (*P < 0.0001, Mann Whitney U test) and KRT6C (*P = 0.0004, Mann Whitney U test) were significantly increased in CBP 
resistant OVCAR-5 CBPR cells compared to parental OVCAR-5 cells. Data for the primary cells is expressed as the mean fold change 
from 3-6 RNA samples from 2 independent experiments. Data for OVCAR5 cells is expressed as the mean fold change ± SEM from 
10 individual RNA samples from 3 independent experiments. (C) K5 immunocytochemistry in serous ovarian cancer cells (OVCAR-5, 
OAW28, OVCAR-3 & COV362) ± 48 hr treatment with CBP IC50 and in parental OVCAR5 and CBP resistant OVCAR5 cells (OVCAR5 
CBPR). (D) K5+ cells are increased following 48 hr treatment with an IC50 dose of CBP and the development of chemoresistance. *P < 0.05 
(unpaired student t test), data is expressed as mean % positive cells ± SEM from 3-4 independent experiments. 
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cells were obtained from Dr Thomas Hamilton (Fox Chase 
Cancer Center, PA, USA) and the peritoneal cells, LP-9 
were purchased from Coriell Cell Repositories (NJ, USA). 
COV362 and OAW28 were purchased from the European 
Collection of Cell culture (ECCC). OV-90, OVCAR-3, 
SKOV-3 and OVCAR-5 cell lines were grown in RPMI 
1640 media (cat no. R8758, Sigma Adrich, St Louis, USA) 
whilst COV362 and OAW28 were grown in DMEM media 
(cat no. 10567-022, Gibco, Life Technologies, Mulgrave, 
Vic, Australia). All cell lines are cultured with 10% fetal 
bovine serum (Sigma Aldrich) and maintained at 37°C in 
an environment of 5% CO2. OVCAR-5 cells were made 
resistant to carboplatin (OVCAR-5 CBPR) following 
treatment with 8 cycles of carboplatin (CBP, 50 µM, 
Hospira Australia Pty, Ltd). The OVCAR-5 CBPR cells 
exhibited an IC50 (273 µM) to carboplatin that was nearly 
3-fold higher than that for the parental OVCAR-5 cells 
(99 µM) (data not shown)
Primary ovarian cancer cells were derived from 
ascites collected from serous ovarian cancer patients 
after informed consent and with approval of the Royal 
Adelaide Hospital Human Ethics Committee as described 
previously [61]. All primary cells were grown in Advanced 
RPMI 1640 medium (cat no 12633-020) supplemented with 
4 mM L-glutamine, 10% FBS (Sigma Aldrich, St Louis, 
MO, USA) and antibiotics (100 U penicillin G, 100 µg/ml 
streptomycin sulfate and 100 µg/ml amphotericin B, Sigma 
Aldrich). Methods were carried out in accordance with the 
approved guidelines. The clinicopathological characteristics 
of the patients whose ascites was used to isolate the primary 
cells are shown in Supplementary Table 2. 
Quantitative real-time PCR
Cells were plated at 5,000 cells in 96 well plates 
and cultured until confluence for 72–96 hr. Total RNA 
was isolated and reverse transcribed using the TaqMan® 
Gene expression Cells-to-CT™ kit (Applied Biosystems, 
Mulgrave, Victoria, Australia), as per the manufacturer’s 
instructions. Briefly, lysis solution with DNAse was added 
to each well and incubated for 5 min at room temperature. 
Stop solution was then added to each well and mixed. The 
lysate (10 µl) was added to a 40 µl reverse transcription 
master mix and reverse transcribed for 1 hr. Resultant 
cDNA was stored as 50 µl aliquots at −20°C for qRT-
PCR analysis. qRT-PCR reactions were performed on 
triplicate samples using TaqMan® primer sets for KRT5 
(Hs00361185_m1), KRT6C (Hs00752476_s1) using the 
Quantstudio 12K Flex Real Time PCR System (Applied 
Biosystems). Briefly, PCR reactions were made up to 
10 µl and contained TaqMan® Gene Expression Master 
Mix (2×), primers for the gene of interest, nuclease free 
water, and the sample cDNA. PCR cycling conditions 
were as follows: 50°C for 2 min, 95°C for 10 min (with 40 
cycles following of 95°C for 15 sec), and 60°C for 1 min. 
CT values were normalised to the house keeping gene 
β-actin (Human ACTB 4333762, Applied Biosystems) and 
calibrator using the 2−∆∆CT method. 
Western immunoblotting
OVCAR-5, OVCAR-3, OV-90, SKOV-3, and 
LP-9 cells a were grown to 80% confluence in 75 cm2 
flasks (Corning, Sigma Aldrich) and cell extracts were 
collected. Cells were dislodged using a cell scraper and 
resuspended in 200 μl of RIPA buffer (1% Nonidet P-40, 
1% sodium deoxycholate, 0.1% SDS, 0.15 M sodium 
chloride, 50 mM Tris- HCL and 1 mM EDTA, pH 8.0 
with protease inhibitor) and spun at 7000 rpm (Eppendorf 
5424 centrifuge) for 10 min and stored at −20°C. Equal 
amounts of protein were electrophoresed and transferred 
to PVDF membranes (GE Healthcare, Little Chalfont, 
England) as described previously [3]. Proteins bands 
were detected with mouse monoclonal K5/6 antibody 
(1/200, clone D5/16 B4, Dako, Glostrup, Denmark) or K5 
rabbit monoclonal antibody (1/5000, clone EPR1600Y, 
Abcam Ab75869, Melbourne, Vic, Australia) with 
anti-mouse or anti-rabbit IgG peroxidase-conjugated 
secondary antibodies, enhanced chemiluminescence, 
and autoradiography as described previously [3]. β-actin 
mouse monoclonal antibody (1/10,000, clone AC-15, 
Sigma Aldrich A3854) was used as a loading control. 
Ovarian cancer tissue extracts prepared in RIPA buffer 
with high K5/6 and K5 immunostaining used as positive 
controls for the western blots. 
Tissue cohort
Tissue sections were obtained from formalin fixed 
paraffin embedded blocks from normal ovaries (n = 8), 
benign serous tumors (n = 8), serous borderline tumors 
(n = 10), and primary advanced stage (FIGO stage III/
IV) serous ovarian cancers (n = 126). The cancer tissues 
were assembled into tissue microarrays (TMAs, 1 mm 
triplicate cores) from archived tissue (cancer areas 
identified by pathologist, AR) obtained from serous 
ovarian cancer patients diagnosed between 1988 and 
2012. An additional 21 tissues were obtained from patients 
with high grade serous cancer after they had received 
neoadjuvent chemotherapy. Approval was obtained from 
the Royal Adelaide Hospital Human Ethics Committee 
and methods were carried out in accordance with the 
approved guidelines. Detailed pathological and clinical 
characteristics of the patient samples are summarized in 
Supplementary Table 3. 
Analysis of public databases
The Kaplan-Meier plotter tool (http:/kmplot.
com/analysis/) was used to generate survival curves 
combining KRT5 (Affymetrix probe 201820_at) and 
KRT6 (Affymetrix probe 209126_x_at detects all KRT6 
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isoforms) mRNA data from 13 public ovarian cancer 
datasets [31]. The Kaplan-Meier analysis was performed 
on the 2015 version database (n = 1648) and patients 
were split by the best cut-off selected by the online plotter 
tool [31]. PFS and OS data was available for 922 and 956 
stage III/IV serous ovarian cancer patients, respectively. 
cBioPortal (http://www.cbioportal.org/) was used to assess 
correlations between KRT5 and KRT6 expression levels 
with clinicopathological parameters features in the TCGA 
2011 dataset [62, 63]. 
Immunohistochemistry
Immunohistochemistry was performed as previously 
described [64]. Briefly, tissue sections (5 µm) underwent 
microwave antigen retrieval for 10 minutes at 100°C 
in a steam microwave (Sixth Sense, Whirlpool, VIC, 
Australia) in 10 mM Tris buffer, 1 mM EDTA (pH 
9.0). Sections were incubated overnight with mouse 
monoclonal antibody which detects both K5 and K6 
(1/50, clone D5/16 B4, Dako) or K5 rabbit monoclonal 
antibody (1/400, clone EPR1600Y, Abcam Ab75869), 
in blocking buffer (5% normal goat serum) at 4°C. 
Visualization of immunoreactivity was achieved using 
biotinylated anti-mouse or anti-rabbit immunoglobulins 
streptavidin-peroxidase conjugate, diaminobenzidine 
substrate as described previously [3]. Human skin was 
used as a positive control and negative controls included 
tissues incubated with no primary antibody or with 
mouse or rabbit immunoglobulins. Slides were digitally 
scanned using the NanoZoomer Digital Pathology System 
(Hamamatsu Photonics, SZK, Japan) and images were 
collected using NDP view imaging software (NDP scan 
software v2.2, Hamamatsu Photonics). K5/6 or K5 
expression was quantified using a visual grading system 
based on the extent of staining. Percentage of positive 
tumor cells was graded on a scale from 0–3; 0 = none, 
1 = 1–9 %, 2 = 10–50%, 3 = > 50% by two independent 
assessors used previously for breast cancer [65, 66]. 
High K5/6 or K5 immunostaining was defined as ≥ 10% 
positivity and < 10% was defined as low K5/6 or K5 
immunostaining.
Immunocytochemistry
Ovarian cancer cells (2 × 104 cells/well) were plated 
in 8 well tissue culture chamber slides (Nunclon™ Lab-
Tek II Chamber slide, RS Glass Slide, Naperville, IL) 
in 500 µl 10% FBS RPMI for 24 h and treated for 48 h 
with IC50 concentration of CBP or control media. CBP 
IC50 for serous ovarian cancer cell lines were previously 
determined to be ~100 µM for OVCAR-5, OVCAR-3 
and OAW28 cells and 500 µM for COV362 cells. Cells 
were fixed with cold 100% methanol (5 min) and cold 
100% acetone (3 min), washed with PBS and blocked 
with 5% goat serum and incubated overnight with 
rabbit monoclonal K5 (1/50, clone EPR1600Y, Abcam 
Ab75869). K5 was visualized with goat anti-rabbit Alexa 
Fluor® 488 (1/200, 1hr at RT, catalogue no. A11034, 
Molecular Probes, Life Technologies) and slides were 
mounted with Prolong Gold Antifade Mountant with 
Dapi (catalogue no. P36941, Molecular Probes, Life 
Technologies). Cells were viewed with an epifluorescence 
microscope (BX50, Olympus Australia) and imaged using 
a 40× objective and a Spot RT digital camera (Diagnostic 
Instruments, Sterling Heights, MI). Negative controls 
included rabbit immunoglobulin or no primary antibody. 
The percentage of K5+ cells in controls and following 
carboplatin treatment were evaluated in 5 high power 
images (~100–200 cells).
Statistical analyses
All statistical analyses were performed using 
SPSS for Windows software (Version 21.0, SPSS Inc., 
Chicago, IL, USA). Chi-squared test was performed 
to determine the correlation of K5/6 immunostaining 
in ovarian tumor tissues with clinical and pathological 
parameters. The Mann Whitney U test was used to assess 
differences between KRT5 and KRT6C expression in 
the chemotherapy sensitive and chemotherapy resistant 
primary serous ovarian cancer cells and the parental 
OVCAR-5 and carboplatin resistant OVCAR-5 CBPR 
cells. The one way ANOVA with the Dunnet C Post hoc 
test was used to assess differences between Z scores for 
KRT5 and KRT6 expression and clinical parameters as data 
was normally distributed. Kaplan-Meier and univariate 
Cox Regression analyses were performed to assess the 
association of K5/6 expression in the advanced stage 
ovarian cancer TMA cohort with PFS and OS. Relapse 
or death due to ovarian cancer was used as the endpoint 
to determine whether KRT5, or KRT6C expression and 
K5/6 positivity was associated with PFS or OS. Statistical 
significance was accepted at P < 0.05. 
Abbreviations
CBP, carboplatin CM, conditioned media; HR; 
hazard ratio, PFS, progression-free survival; OSE, ovarian 
surface epithelium; OS, overall survival; TMA, tissue 
microarray.
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